{"filing":{"accession_number":"0001581280-26-000044","cik":"0001581280","ticker":"TWST","company_name":"Twist Bioscience Corp","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"twist-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581280/000158128026000044/twist-20260803.htm"},"events":[{"id":23426,"run_id":21179,"accession_number":"0001581280-26-000044","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Twist Bioscience's fiscal third quarter 2026 (ended June 30, 2026), disclosing quarterly financial results including revenue of $118.4 million (23% YoY growth), gross margin of 52.8%, and net loss of $35.1 million. The company also raised full-year FY2026 revenue guidance to $456-$457M. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings announcements.","company_name":"Twist Bioscience Corp","ticker":"TWST","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23645,"accession_number":"0001581280-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Twist Bioscience's fiscal third quarter 2026 (ended June 30, 2026), disclosing quarterly financial results including revenue of $118.4 million (23% YoY growth), gross margin of 52.8%, and net loss of $35.1 million. The company also raised full-year FY2026 revenue guidance to $456-$457M. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:30:58.119273+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23645,"accession_number":"0001581280-26-000044","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Twist Bioscience's fiscal third quarter 2026 (ended June 30, 2026), disclosing quarterly financial results including revenue of $118.4 million (23% YoY growth), gross margin of 52.8%, and net loss of $35.1 million. The company also raised full-year FY2026 revenue guidance to $456-$457M. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings announcements.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:30:58.119273+00:00","company_name":"Twist Bioscience Corp","ticker":"TWST","filing_date":"2026-08-03"}]}